AVTX vs JPM · P/E 0.0, rev $441.0K vs P/E 14, rev $182.45B
Avalo Therapeutics Inc (AVTX) versus JPMorgan Chase & Co (JPM) — a side-by-side from cached financials, not a winner call.
Avalo Therapeutics Inc (AVTX) is a biotechnology company listed on US.
JPMorgan Chase & Co (JPM) is a banks - diversified company listed on US. It is led by Jamie Dimon.
Latest reported AVTX revenue for 2024-12-31 was $441.0K. Net income was -$35.1M. Revenue was down 77.1% from 2023-12-31 to 2024-12-31. AVTX currently screens at market cap $51.5M and trailing P/E 0.0.
Latest reported JPM revenue for 2025-12-31 was $182.45B. Net income was $57.05B. Revenue was up 2.8% from 2024-12-31 to 2025-12-31. JPM currently screens at market cap $805.69B and trailing P/E 14.2.
AVTX currently screens at market cap $51.5M and trailing P/E 0.0. JPM currently screens at market cap $805.69B and trailing P/E 14.2.
Not investment advice. Open the AVTX and JPM stock pages for the full models.
Not investment advice.